Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

682
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
682
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

413
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
413
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

698
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
698
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.1K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

3.7K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spanish Clinical Practice Guidelines for the Diagnosis and Management of Alpha-1 Antitrypsin Deficiency: 2026 Update.

Archivos de bronconeumologia·2026
Same author

A Real-World Evaluation of Therapeutic Inertia in Patients with Severe Uncontrolled Chronic Obstructive Pulmonary Disease.

International journal of chronic obstructive pulmonary disease·2026
Same author

Longitudinal Validation of the RADAR Score in Primary Care: Prognostic Value for Exacerbations and Short-term Changes in Health and Control Status.

Archivos de bronconeumologia·2026
Same author

Kalinix<sup>®</sup>, an innovative, intelligent, non-invasive, and self-adaptive medical device for effective OSA management.

Sleep & breathing = Schlaf & Atmung·2026
Same author

Clinical protocol for the use of biologic therapy in COPD.

Respiratory medicine·2026
Same author

Determinants of Inhaler Choice at Hospital Discharge.

Medical sciences (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jan 7, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.4K

Deconstructing Therapeutic Failure with Inhaled Therapy in Hospitalized Patients: Phenotypes, Risk Profiles, and

Myriam Calle Rubio1,2,3, Soha Esmaili2,4,5, Juan Luis Rodríguez Hermosa1,2,6

  • 1Pulmonology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.

Biomedicines
|December 30, 2025
PubMed
Summary
This summary is machine-generated.

Hospitalized patients on inhaled therapy experience failure due to distinct factors, not uniform problems. Identifying specific drivers of inhaler misuse and clinical inertia allows for personalized treatment strategies.

Keywords:
clinical inertiaclinical phenotypeshospitalized patientsinhaled therapyinhaler techniquetherapeutic failure

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.4K
Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation
09:42

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

13.9K

Related Experiment Videos

Last Updated: Jan 7, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.4K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.4K
Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation
09:42

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

13.9K

Area of Science:

  • Pulmonary Medicine
  • Clinical Pharmacy
  • Health Services Research

Background:

  • Hospitalized patients on chronic inhaled therapy face high rates of treatment failure.
  • Current management often overlooks patient heterogeneity, treating failure as a uniform issue.
  • Clinical inertia is a key driver of failure, but its underlying factors are diverse.

Purpose of the Study:

  • To investigate patient heterogeneity in inhaled therapy failure.
  • To identify distinct predictors of critical inhaler errors and clinical inertia.
  • To explore patient phenotypes and their impact on in-hospital care and outcomes.

Main Methods:

  • Unsupervised clustering of 499 hospitalized adults on chronic inhaled therapy.
  • Multivariable logistic regression to model predictors of inhaler errors and clinical inertia.
  • Identification of three forms of clinical inertia: Therapeutic Class (TCI), Device-Level (DLI), and Adherence-Related (ARI).

Main Results:

  • Inhaler misuse linked to knowledge gaps and low inspiratory flow, not self-reported adherence.
  • Distinct predictors identified for TCI (potency), DLI (lack of training), and ARI (complexity).
  • Two patient phenotypes emerged: 'Unassessed/Older' and 'Assessed/Younger', influencing care pathways but not mortality.

Conclusions:

  • Therapeutic failure in inhaled therapy is predictable and driven by specific, non-overlapping factors.
  • Deconstructing failure reveals actionable drivers of inhaler misuse and clinical inertia.
  • Findings support a precision medicine framework for inhaled therapy, moving beyond generic interventions.